Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (9)
  • SARS-CoV
    (4)
  • Antibiotic
    (3)
  • HCV Protease
    (3)
  • Microtubule Associated
    (3)
  • Akt
    (2)
  • Antibacterial
    (2)
  • Autophagy
    (2)
  • Endogenous Metabolite
    (2)
  • Others
    (13)
Filter
Search Result
Results for "

huh7 cells

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    40
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    7
    TargetMol | Natural_Products
  • Cell Research
    1
    TargetMol | Inhibitors_Agonists
Lin281632
Lin-281632, Lin-28 1632, Lin28 1632, Lin 281632, Lin 28 163
T27835108825-65-6
Lin28 1632 is an inhibitor of RNA binding protein Lin28. It promotes mESC differentiation. Lin281632 is also bromodomain inhibitor.
  • $30
In Stock
Size
QTY
Sorafenib
Bay 43-9006
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
BLU0588
T601692810747-78-3In house
BLU0588 is a selective PRKACA inhibitor. BLU0588 inhibits PRKACA catalytic activity with a half-maximal inhibitory concentration (IC50) of 1 nM.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Pevonedistat
MLN4924
T6332905579-51-3
Pevonedistat (MLN4924) is a potent and selective NEDD8 activating enzyme (NAE) inhibitor (IC50=4.7 nM) with therapeutic potential for myelodysplastic syndromes (MDS) and antitumor activity.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Leupeptin Hemisulfate
T6564103476-89-7
Leupeptin hemisulfate is a protease inhibitor with cell membrane-permeable, reversible, competitive, and oral activities. Leupeptin hemisulfate inhibits the activity of Cathepsin B, Cathepsin H, and Cathepsin L, and blocks fusion of amphipathic lysosomes. Leupeptin hemisulfate also has anti-inflammatory activity.
  • $47
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
BMS-929075
BMS929075, BMS 929075
T268631217338-97-0In house
BMS-929075 is an orally active HCV NS5B replicase (HCV NS5B replicase) palm site variant inhibitor with potency, high oral bioavailability and pharmacokinetic parameters.BMS-929075 shows cytotoxicity.
  • $190
In Stock
Size
QTY
Rifampicin
Rimactane, Rifamycin AMP, Rifampin
T068113292-46-1
Rifampicin (Rifamycin AMP) is a broad-spectrum antibiotic. Rifampicin has a strong antibacterial effect against Mycobacterium tuberculosis and is also effective against gram-positive and gram-negative bacteria and viruses.
  • $45
In Stock
Size
QTY
TargetMol | Citations Cited
Berberine
Umbellatine, Berberin
T4S07972086-83-1
1. Berberine (Umbellatine) is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism. 2. Berberine may as a broad-spectrum anti-microbial medicine, a complementary therapeutic agent for HIV/AIDS. 3. Berberine seems to act as an herbal antidepressant and a neuroprotector against neurodegenerative disorders. 4. Berberine is used in histology for staining heparin in mast cells. As a natural dye, berberine has a colour index of 7516. 5. Berberine reduces hepatic fat content in rats with nonalcoholic fatty liver disease; also prevents proliferation of hepatic stellate cells (HSCs), which are central for the development of fibrosis during liver injury. 6. Berberine can ameliorate proinflammatory cytokines-induced intestinal epithelial tight junction damage in vitro, and berberine may be one of the targeted therapeutic agents that can restore barrier function in intestinal disease states. 7. Berberine has antineoplastic effects, including breast cancer, leukemia, melanoma, epidermoid carcinoma, hepatoma, pancreatic cancer, oral carcinoma, tongue carcinoma, glioblastoma, prostate carcinoma and gastric carcinoma, etc.
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
ITMN4077
T9249790305-05-4
ITMN4077 has antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication with an EC50 of 2.131μM.
  • $30
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Tirbanibulin Mesylate
KX2-391 Mesylate, KX01 Mesylate
T156751080645-95-9
Tirbanibulin Mesylate (KX01 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).
  • $32
In Stock
Size
QTY
SARS-CoV-2-IN-96
T200648
SARS-CoV-2-IN-96 (compound 12b) acts as an inhibitor for both HCoV-OC43 (EC50= 97 nM) and SARS-CoV-2 (EC50= 45 nM), while displaying low cytotoxicity in Huh7 cells (CC50=10 μM).
  • Inquiry Price
Size
QTY
CV-4-26
T200708
CV-4-26 (Compound 22) acts as a covalent inhibitor of TEAD. By inhibiting YAP TEAD-driven transcription, it diminishes the expression of CTGF and CYR61. Furthermore, CV-4-26 impedes colony formation in Huh7 and HepG2 cells, inducing cell cycle arrest and apoptosis (apoptosis). This compound demonstrates anti-tumoral activity against hepatocellular carcinoma (HCC) and hepatoblastoma (HB).
  • Inquiry Price
Size
QTY
Antiproliferative agent-59
T201186
Antiproliferative agent-59 (Compound 14u) acts as an inhibitor of tubulin polymerization. Demonstrating anticancer activity in Huh7, SGC-7901, and MCF-7 cell lines, this compound achieves IC50 values of 0.03, 0.18, and 0.13 μM, respectively. Additionally, it arrests the cell cycle at the G2 M phase and induces apoptosis in Huh7 cells. In a xenograft mouse model utilizing Huh7 cells, Antiproliferative agent-59 exhibits antitumor effects against hepatocellular carcinoma without significant toxicity.
  • Inquiry Price
Size
QTY
MTI013
T201844
MTI013 is a selective inhibitor of SARS-CoV-2 nsp14 Mtase (IC50: 2.98 µM) and an antiviral agent (IC50: 10.33 µM in HCoV-229E infected Huh7 cells). Additionally, MTI013 demonstrates synergistic antiviral effects when used in conjunction with the RdRp inhibitor SHEN26.
  • Inquiry Price
10-14 weeks
Size
QTY
SHP2-IN-33
T2036052894017-46-8
SHP2-IN-33 (Compound D13) is an allosteric inhibitor of SHP2, exhibiting an IC50 of 1.2 μM against SHP2. It demonstrates an antiproliferative IC50 of 38 μM in Huh7 cells by blocking the G0 G1 cell cycle, inducing apoptosis (Apoptosis), and inhibiting the MAPK signaling pathway. In a Huh7 xenograft mouse model, SHP2-IN-33 shows significant antitumor activity and favorable pharmacokinetic properties, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 holds potential for research involving SHP2-associated tumor diseases.
  • Inquiry Price
10-14 weeks
Size
QTY
Tubulin polymerization-IN-75
T2042315325-66-6
Tubulin polymerization-IN-75 (Compound 6) is an inhibitor of tubulin polymerization, with an IC50 value of 30 μM. It effectively suppresses the proliferation of cancer cells Huh7 and 293T, demonstrating IC50 values of 14.3 μM and 13.8 μM, respectively.
  • Inquiry Price
10-14 weeks
Size
QTY
PLK1-IN-15
T2076413068529-37-0
PLK1-IN-15 is a PLK1 inhibitor with an IC50 of 38.5 nM. It exhibits antiproliferative effects on HepG2, Huh7, H1299, and A549 cells, with IC50 values of 2.03, 2.08, 4.79, and 17.11 μM, respectively. Additionally, PLK1-IN-15 can induce cell cycle arrest in the G2/M phase and trigger apoptosis (Apoptosis), demonstrating anticancer activity.
  • Inquiry Price
10-14 weeks
Size
QTY
PROTAC PAPD5 degrader 1
T209430
PROTACPAPD5 degrader 1 (compound 12b) demonstrates the ability to inhibit hepatitis A virus (HAV) and hepatitis B virus (HBV) both in vitro and in vivo, with an IC50 of 10.59 μM and a CC50 greater than 50 μM in Huh7 cells.
    Inquiry
    FGFR4-IN-20
    T209951
    FGFR4-IN-20 (comp 11) is an orally active and selective FGFR4 inhibitor, demonstrating IC50 values of 19 nM against Huh7 cells and 36 nM for FGFR4 kinase. It is utilized in hepatocellular carcinoma research.
      Inquiry
      Anticancer agent 222
      T210103
      Anticanceragent 222 (Compound 19) is an orally active anticancer agent that demonstrates significant anticancer activity against Huh7, FOCUS, SNU475, SNU182, HepG2, and Hep3B cells, with IC50 values ranging from 2.9 to 9.3 μM.
        Inquiry
        KKJ00626
        KKJ-00626,KKJ 00626
        T2773351646-17-4
        KKJ00626, an inhibitor of HBV virus, inhibits HBV replication in transfected Huh7 cells.
        • $1,520
        6-8 weeks
        Size
        QTY
        KSJ0001
        KSJ-0001,KSJ 0001
        T2775074805-39-3
        KSJ0001, a HBV virus inhibitor, inhibits HBV replication in transfected Huh7 cells.
        • $1,520
        6-8 weeks
        Size
        QTY
        Homoharringtonine
        Omacetaxine mepesuccinate, Myelostat, HHT, Ceflatonin
        T338026833-87-4
        Homoharringtonine (HHT) is a natural alkaloid that inhibits the translation of proteins and is cytotoxic. Homoharringtonine acts on the ribosomes of tumor cells to inhibit the elongation step of protein translation, thereby inhibiting protein synthesis, and has antitumor activity.
        • $50
        In Stock
        Size
        QTY
        TargetMol | Inhibitor Sale
        TargetMol | Citations Cited
        YW1128
        T355472131223-64-6
        YW1128 is an inhibitor of Wnt/β-catenin signaling with an IC50 value of 4.1 nM in a reporter assay.1 It decreases protein levels of β-catenin in the presence of the GSK3β inhibitor lithium chloride and increases protein levels of Axin1 in HEK293 cells. YW1128 decreases lipid accumulation and the expression of gluconeogenic and lipogenic genes in Huh7 cells. It decreases the hepatic expression of Wnt target genes, improves glucose tolerance, and prevents body weight increases and hepatic lipid accumulation in mice fed a high-fat diet, but not mice fed normal chow, when administered at a dose of 40 mg/kg every other day for 11 weeks.References1. Obianom, O.N., Ai, Y., Li, Y., et al. Triazole-based inhibitors of the Wnt/β-catenin signaling pathway improve glucose and lipid metabolism in diet-induced obese mice. J. Med. Chem. 62(2), 727-741 (2019). YW1128 is an inhibitor of Wnt/β-catenin signaling with an IC50 value of 4.1 nM in a reporter assay.1 It decreases protein levels of β-catenin in the presence of the GSK3β inhibitor lithium chloride and increases protein levels of Axin1 in HEK293 cells. YW1128 decreases lipid accumulation and the expression of gluconeogenic and lipogenic genes in Huh7 cells. It decreases the hepatic expression of Wnt target genes, improves glucose tolerance, and prevents body weight increases and hepatic lipid accumulation in mice fed a high-fat diet, but not mice fed normal chow, when administered at a dose of 40 mg/kg every other day for 11 weeks. References1. Obianom, O.N., Ai, Y., Li, Y., et al. Triazole-based inhibitors of the Wnt/β-catenin signaling pathway improve glucose and lipid metabolism in diet-induced obese mice. J. Med. Chem. 62(2), 727-741 (2019).
        • $223
        35 days
        Size
        QTY